On May 21, 2025 ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed preclinical biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, reported that its subsidiary, ME Therapeutics Inc., is receiving advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) (Press release, ME Therapeutics, MAY 21, 2025, View Source [SID1234653284]). The project will support the research and development of ME Therapeutic’s mRNA therapeutic program targeting myeloid cell biology for the treatment of cancer and inflammatory disease.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to receive this support from NRC IRAP, which builds on advisory services and funding received in past years, to allow us to further advance preclinical studies for our mRNA therapeutic candidates that target key myeloid cell pathways," said Salim Dhanji, CEO of ME Therapeutics. "Our team at ME Therapeutics passionately believes myeloid cell-derived mRNA therapies represent the next wave of treatments for patients with cancer and inflammatory disease who today have limited treatment options, and we are committed to bringing these potential new approaches to the clinic as soon as possible."
ME Therapeutics’s proprietary mRNA sequences have been engineered to encode for proteins that can modify the immune response in vivo in a targeted manner. Their lead mRNA therapeutic candidate is specifically designed to modulate immune cells in the tumour microenvironment and stimulate an anti-cancer immune response. Preclinical testing has already demonstrated encouraging anti-cancer activity in a mouse model of colorectal cancer. In addition, ME Therapeutics is exploring design modifications of its mRNA candidates to modulate mRNA expression in a tissue-specific manner for increased efficacy and safety.